key: cord-0863454-4nejdwb2
authors: Lederer, Katlyn; Bettini, Emily; Parvathaneni, Kalpana; Painter, Mark M.; Agarwal, Divyansh; Lundgreen, Kendall A.; Weirick, Madison; Muralidharan, Kavitha; Castano, Diana; Goel, Rishi R.; Xu, Xiaoming; Drapeau, Elizabeth M.; Gouma, Sigrid; Ort, Jordan T.; Awofolaju, Moses; Greenplate, Allison R.; Le Coz, Carole; Romberg, Neil; Trofe-Clark, Jennifer; Malat, Gregory; Jones, Lisa; Rosen, Mark; Weiskopf, Daniela; Sette, Alessandro; Besharatian, Behdad; Kaminiski, Mary; Hensley, Scott E.; Bates, Paul; Wherry, E. John; Naji, Ali; Bhoj, Vijay; Locci, Michela
title: Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
date: 2022-02-02
journal: Cell
DOI: 10.1016/j.cell.2022.01.027
sha: 8cd4ac012dcd3782a3a19ade436780d1b37aa419
doc_id: 863454
cord_uid: 4nejdwb2

Vaccine-mediated immunity often relies on the generation of protective antibodies and memory B cells, which commonly stem from germinal center (GC) reactions. An in-depth comparison of the GC responses elicited by SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals has not yet been performed due to the challenge of directly probing human lymph nodes. Herein, through a fine-needle-aspiration-based approach, we profiled the immune responses to SARS-CoV-2 mRNA vaccines in lymph nodes of healthy individuals and kidney transplant recipients (KTXs). We found that, unlike healthy subjects, KTXs presented deeply blunted SARS-CoV-2-specific GC B cell responses coupled with severely hindered T follicular helper cell, SARS-CoV-2 receptor-binding-domain-specific memory B cell and neutralizing antibody responses. KTXs also displayed reduced SARS-CoV-2-specific CD4 and CD8 T cell frequencies. Broadly, these data indicate impaired GC-derived immunity in immunocompromised individuals, and suggest a GC-origin for certain humoral and memory B cell responses following mRNA vaccination.

2. 3. when the outlier in the Full S + RBD + GC B cell frequency data set was excluded (data not shown, was also detectable at variable levels in peripheral blood samples of vaccinated HDs ( Figure S3G ). 219 Furthermore, SARS-CoV-2-specific plasmablasts were also increased in the draining LNs and 220 blood after the second immunization ( Figure 3E -F and S3H). However, no correlation was found 221 between the total or SARS-CoV-2-specific plasmablast populations detected in FNA and blood 222 samples ( Figure S3I and S3J). In sum, the data obtained in our study indicate that two doses of 223 SARS-CoV-2 mRNA vaccines can elicit SARS-CoV-2 S-and RBD-specific MBCs as well as a 224 population of plasmablasts in draining LNs.

MBC and nAb responses in kidney transplant recipients. 228 To determine the capacity of immunocompromised individuals to form GC responses to CoV-2 mRNA vaccines, 13 KTXs were enrolled. Due to withdrawal of consent (n=1), failure to 230 undergo collection procedures (n=1), and lack of sufficient cells (n=1), 10 patients who were a 231 median 80 days post-transplant (range -9-1894 days) were included in further analysis (Table S1 ).

One KTX was previously infected with SARS-CoV-2 (shown as gray square symbol). The KTXs 233 in our cohort presented normal Ab responses established prior to transplantation, including normal 234 levels of antigen-specific IgG induced by tetanus toxoid (TT), mumps, rubella and measles-235 containing vaccines ( Figures S4A-D) . Similarly, most KTXs tested also presented detectable levels 236 of anti-CMV (10/13) and anti-EBV (13/13) IgGs (Table S2) . Full S + RBDbut not Full S + RBD + MBCs were also detectable in draining LNs of most donors 258 after the administration of two vaccine doses ( Figure S4H ). These data were only partially 259 confirmed in blood ( Figure S4I ). Interestingly, when HDs and KTXs were analyzed together, a immunizations, whereas the remaining 5/8 of the patients had SARS-CoV-2 binding Abs below 281 the limit of detection ( Figure 4H -I). Similar to previous data in HDs (Amanat et al., 2021) , SARS- stimulation with a SARS-CoV-2 peptide megapool (Grifoni et al., 2020a) . Similar to previous 318 reports ( Apostolidis et al., 2021; Painter et al., 2021) , we detected significantly increased 319 frequencies of AIM + (CD200 + CD40L + ) SARS-CoV-2-specific CD4 T cells in blood samples of 320 all HDs after the first and second vaccine administration ( Figure 6A -B and Figure S6A ). In GCs, presented deeply blunted nAb production. Although to a lower degree, we also found that 402 bona fide Tfh cells in draining LNs correlated with nAb production, while activated Tfh cells in 403 blood were a less reliable predictor of nAb generation. Additionally, in our study GC formation 404 appeared to be tightly connected with the capacity to produce class-switched RBD-specific MBCs.

These findings provide valuable insights on the otherwise poorly understood processes by which 406 nAbs and MBCs are formed in humans after immunization with SARS-CoV-2 mRNA vaccines. is unlikely to be entirely dependent on the variables listed above, larger confirmatory studies with 510 a more balanced control of ethnicity, age and gender will be important to strengthen our findings.

Another aspect that was not possible to elucidate in our study, due to the paucity of available 512 biospecimens, is whether the Full S + RBD -MBCs that are present in KTXs following SARS-CoV-513 2 mRNA vaccination are pre-existing MBCs specific for seasonal human coronaviruses. These performed. * P  0.05, ** P  0.01, **** P  0.0001. See also Figure S1 and Table S4 . Figure S2 and Table S4 . Figure S3 and Table S4 . Table S4 . In (A), for HDs and KTXs n=3. In (C), for HDs: n = 13; for KTXs: n = 3 for V2 and n = 7 for V3; 655 circles represent HDs, triangles represent KTXs, a gray square is used to indicate a KTX with a 656 prior SARS-CoV-2 infection. In (C), data is shown as mean ± SEM. Statistical analysis: In (C), a 657 paired Mann-Whitney U test with continuity correction was performed. * P  0.05, ** P  0.01.

See also Table S4 . correlations were determined using the Spearman's rho with a 95% confidence interval. * P  0.05.

See also Table S4 . Table   745 S4. All unique reagents generated in this study will be available from the Lead Contact upon 852 reasonable request.

Data and code availability 854 o All raw data reported in this paper will be shared by the Lead Contact upon request. Table S1 ). The healthy donor cohort ranged in age from 23 to 76 years old and was composed of 864 six males and nine females. The KTX recipient cohort ranged in age from 28 to 70 years old and Labeling of SARS-CoV-2 full-length spike protein: Full-length, biotinylated spike protein was 907 purchased from R&D Systems. Streptavidin-conjugated BV421 (Biolegend) was then added at a 908 6:1 molar ratio (biotinylated-protein to streptavidin-conjugate) on ice for 1 hour.

Labeling of HA and SARS-CoV-2 RBD: Recombinant HA and RBD was produced as previously 910 described (Amanat et al., 2020; Margine et al., 2013; Stadlbauer et al., 2020) . To create 911 fluorescently labeled RBD tetramers, RBD was biotinylated using the EZ-Link Micro Sulfo-NHS-

Biotinylation Kit (ThermoFisher). Streptavidin-conjugated PE was then added at a 6:1 molar ratio 913 (biotinylated-protein to streptavidin-conjugate). Specifically, after the volume of fluorochrome 914 needed to achieve a 6:1 molar ratio was determined, the total volume of fluorochrome was split 915 into 10 subaliquots. These subaliquots were then added, on ice, to the biotinylated protein and 916 mixed by pipetting every 10 minutes (for a total of 10 additions). FlowJo v.10 (Treestar). Frequency values for individual cell populations are provided in Table S4 . peptides spanning the entire sequence of the Spike protein and was prepared as previously described (Grifoni et al., 2020b (Grifoni et al., , 2020a . The remainder of the AIM assay was performed and 955 samples were collected and analyzed as previously described (Painter et al., 2021) . The flow 956 cytometry panel used for the the detection of AIM + cell populations is described in Table S5 .

AIM + cells were identified from non-naïve or total T cell populations where indicated. All data 958 from AIM expression assays were background-subtracted using paired unstimulated control In brief: Fine needle aspiration of lymph nodes in humans, reveals that SARS-CoV-2 vaccination induces neutralizing antibody-producing germinal centers, enhanced by repeated vaccination. Conversely, in patients receiving immunosuppressant medication, this process is disrupted resulting in stunted protective immune responses highlighting issues about vaccine and booster efficacy in patients with compromised immune systems.

Surface phenotype and antigenic specificity of human 1078 interleukin 17-producing T helper memory cells

Lipid nanoparticles enhance the efficacy of 1081 mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral 1082 responses

Germinal-Center Organization and Cellular 1084 Dynamics

A serological assay to detect 1087 SARS-CoV-2 seroconversion in humans

SARS-CoV-2 mRNA vaccination induces 1090 functionally diverse antibodies to NTD, RBD, and S2

SARS-CoV-2 infections elicit higher 1093 levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger 1128 RNA Vaccine in Solid Organ Transplant Recipients

Immune response to an adjuvanted influenza A H1N1 1131 vaccine (Pandemrix®) in renal transplant recipients

Influenza A/H1N1 Vaccine in 1134

Patients Treated by Kidney Transplant or Dialysis: A Cohort Study

Potent neutralizing antibodies 1138 from COVID-19 patients define multiple targets of vulnerability

The first 12 months of COVID-19: a timeline 1140 of immunological insights

High-affinity

CoV-2 can be made in the absence of T follicular helper cells

Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and 1146 inhibiting cyclooxygenase-2 expression

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA 1149 vaccine-elicited antibodies

Impact of Immunosuppression on Recall Immune 1152

Responses to Influenza Vaccination in Stable Renal Transplant Recipients

T Follicular Helper Cell Biology: A Decade of Discovery and Diseases

Cellular and humoral response after 1158 SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

Antibodies elicited by mRNA-1273 vaccination bind more broadly to the 1194 receptor binding domain than do those from SARS-CoV-2 infection

Targets of T Cell Responses to 1197

SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune 1201 Responses to SARS-CoV-2

Randomized Trial of a Third Dose of 1204 mRNA-1273 Vaccine in Transplant Recipients

CXCL13 is a plasma biomarker of germinal 1207 center activity

Normal human lymph node T follicular helper cells and germinal 1211 center B cells accessed via fine needle aspirations

Vaccination establishes clonal relatives of germinal 1214 center T cells in the blood of humans

Circulating CXCR5+PD-1+ response predicts 1217 influenza vaccine antibody responses in young adults but not elderly adults

An mRNA Vaccine 1221 against SARS-CoV-2 -Preliminary Report

CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter 1348 observational study using mRNA-1273 or BNT162b2 mRNA vaccine

The Calcineurin Inhibitor 1378

Tacrolimus Specifically Suppresses Human T Follicular Helper Cells. Front Immunol 9

Safety and Immunogenicity of Two RNA-Based 1381

Covid-19 Vaccine Candidates

mRNA vaccine-elicited antibodies to 1384 SARS-CoV-2 and circulating variants

Naturally enhanced neutralizing breadth 1387 against SARS-CoV-2 one year after infection

Durability of Responses 1390 after SARS-CoV-2 mRNA-1273 Vaccination

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Potently neutralizing and protective human antibodies 1396 against SARS-CoV-2

RRID: AB_2337596 Goat anti-human IgM-HRP Southern Biotech Cat#2020-05; RRID: AB_2795603 Goat anti-human IgA-HRP Southern Biotech Cat#2050-05

Recombinant Spike-Biotin R&D Systems

Ghost Dye Violet 510 Tonbo Cat#13-0870-T500 GolgiStop (Containing Monensin) BD Biosciences

Human TruStain FcX™ (Fc Receptor Blocking Solution) Biolegend Cat#422302 Brilliant Stain Buffer BD Biosciences Cat#563794 ACK Lysing Buffer Gibco

Plasmid: pCG1 SARS-CoV-2 D614G delta18 Bates Lab N/A Plasmid: pCG1 SARS-CoV

Graphpad Prism v9 Graphpad RRID:SCR_002798 FlowJo v10 FlowJo LLC RRID:SCR_008520 Cytobank Premium

temperature for 15 (rubella) or 20 (measles, mumps, and tetanus toxoid) minutes before 100uL of 1014 stop solution was added. Plates were read at 450nM on a Molecular Devices EMax Plus plate 1015 reader. A second order polynomial regression was fit to the data in excel v16.55. All samples were 1016 run as technical duplicates and the values were averaged prior to plotting.